NEW YORK, Nov. 14, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today it will present at the Marcus Evans 10th Annual Commercialization of Regenerative Medicine in London, UK on the 28-30th November 2012. The Company will also be conducting a half-day pre-conference workshop addressing market entry strategies for emerging regenerative medicine companies.
IntelliCell's EVP Clinical Development, Robert Sexauer, stated "Our Company is very pleased to be participating in this well established conference for emerging regenerative medicine technologies. Over the past several years, our management team has processed over 10,000 autologous cellular products and we are happy to share our insights regarding market entry strategies for emerging companies in our industry. We want to see the entire regenerative medicine industry continue to develop compliant processes, systems, and practices for better medicine"
Dr. Steven Victor, Chairman and CEO of IntelliCell stated "This is an exciting time for regenerative medicine companies. IntelliCell is taking a thought leadership role in the translation of technologies from the research laboratories and into clinical practice. Our objective is to continue to harmonize the requirements of regulators, clinicians, and patients receiving these profound new treatments."
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs. The Company has several patent pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative he
|SOURCE IntelliCell BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved